Amgen appoints David W. Gibbs to board of directors
Biotechnology firm Amgen has appointed David W. Gibbs as a member of its board of directors, effective immediately.
Amgen announced on October 26, 2026, that David W. Gibbs has joined the company's board of directors. As part of his appointment, Gibbs will serve on the board’s audit committee as well as the compensation and management development committee.
The addition of Gibbs to the board comes as the pharmaceutical company navigates evolving market demands and maintains its focus on clinical development and commercial operations. Board members are tasked with overseeing corporate governance and financial integrity.
Amgen continues to prioritize board composition to ensure alignment with its long-term strategic objectives in the global biopharmaceutical landscape.